{
  "id": "UCSF_CAPRA_prostate_cancer_risk.v1",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2017-10-07",
      "name": "Syeeda S Farruque",
      "organisation": "Cambio Healthcare Systems",
      "email": "models@cambiocds.com"
    },
    "other_contributors": [
      "Dennis Forslund, Cambio Healthcare Systems",
      "Linda Guttormsdottir"
    ],
    "lifecycle_state": "Author draft",
    "details": {
      "sv": {
        "id": "sv",
        "purpose": "Prognostisk värdering av prostatacancer med hjälp av olika kliniska parametrar.",
        "keywords": [
          "Gleason Score",
          "prostatacancer",
          "PSA",
          "UCSF CAPRA",
          "Gleason"
        ],
        "use": "Maximal poängsumma uppgår till 10p, och baseras på följande parametrar:\nGradering enligt Gleason\nPSA-värde vid diagnos\nÅlder \nKliniskt cancerstadium: antingen 1/2 eller 3a\nAntal procent positiva biopsier\n\nRekommenderad åtgärd:\n- vid mycket låg risk, överväg rutinmässig kontroll\n- vid låg-mellan risk, överväg lokal behandling (kirurgi eller strålning, brachyterapi)\n- vid mellan-hög risk, överväg multimodal/kombinerad behandling (kirurgi med strålning, eller strålning och hormonell behandling)\n- vid mycket hög risk, överväg antingen multimodal/kombinerad ELLER hormonell behandling, samt kliniska prövningar\n\n\nResultatet tolkas enligt:\n                                    Metastasfritt intervall              Överlevnad, prostatacancer    Överlevnad, totalt\n                                    % sannolikhet (95% CI) \t % sannolikhet (95% CI)                        % sannolikhet (95% CI)\nCAPRA Risk Group       5 år \t    10 år                         5 år\t            10 år \t                      5 år \t         10 år\n\nLåg risk                       99.3             97.5                         99.7              97.1                                92.5                   71.4\n(0-2 poäng) \t\n\nMellanrisk                    96.9            93.3                          98.6               91.6                               90.2                   59.7\n(3-5 poäng)\n\nHög risk                       90.4            83.4                          93.4               79.1                               78.7                  42.0 \n(≥6 poäng)\n",
        "misuse": "Ej avsedd för diagnostik.",
        "copyright": "© Cambio Healthcare Systems"
      },
      "en": {
        "id": "en",
        "purpose": "The UCSF (University of California, San Francisco CAPRA (CAncer of the Prostate Risk Assessment) Score uses PSA values and Gleason score grades/patterns among other indicators, to help predict prognosis for patients with prostate cancer.",
        "keywords": [
          "Gleason Score",
          "prostate cancer",
          "PSA",
          "Ucsf capra for prostate cancer risk"
        ],
        "use": "The tool sums the individual variables for a score ranging from 0 to 10. The variables are:\n\nGleason grade/pattern (either 4/5 (primary or secondary) or not)\nPSA values at diagnosis\nAge\nClinical stage of prostate cancer: either 1/2 or 3a are assessed\nPercent biopsy cores positive for cancer.\n\nManagment:\n\n- For very low risk patients, consider routine surveillance.\n- For low to intermediate-risk patients, consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy).\n- For intermediate to high-risk patients, consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).\n- For very high-risk patients, consider either multimodal therapy OR hormonal therapy, and clinical trial enrollment.\n\n\nScore interpretation:\n                                    Metastasis-free interval              Prostate cancer–specific survival    Overall survival\n                                    % likelihood (95% CI) \t                % likelihood (95% CI)                        % likelihood (95% CI)\nCAPRA Risk Group    5-year \t10-year \t                 5-year \t10-year \t                      5-year \t         10-year\n\nLow Risk Group          99.3             97.5                            99.7              97.1                                92.5                   71.4\n(0-2 points) \t\n\nIntermediate Risk        96.9            93.3                            98.6               91.6                               90.2                   59.7\nGroup (3-5 points)\n\nHigh Risk Group          90.4            83.4                            93.4               79.1                               78.7                  42.0 \n(≥6 points)",
        "misuse": "Do not use for diagnostic purposes without also considering a thorough clinical investigation.",
        "copyright": "© Cambio Healthcare Systems"
      }
    },
    "other_details": {
      "references": "Ref. 1: Cooperberg MR, Broering JM, Carroll PR. Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. JNCI Journal of the National Cancer Institute. 2009;101(12):878-887. doi:10.1093/jnci/djp122."
    }
  },
  "definition": {
    "data_bindings": {
      "gt0007": {
        "id": "gt0007",
        "model_id": "openEHR-EHR-OBSERVATION.basic_demographic.v1",
        "template_id": "openEHR-EHR-OBSERVATION.basic_demographic.v1",
        "type": "INPUT",
        "elements": {
          "gt0008": {
            "id": "gt0008",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0008]"
          }
        }
      },
      "gt0009": {
        "id": "gt0009",
        "model_id": "openEHR-EHR-OBSERVATION.basic_demographic.v1",
        "template_id": "openEHR-EHR-OBSERVATION.basic_demographic.v1",
        "type": "OUTPUT",
        "elements": {
          "gt0010": {
            "id": "gt0010",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0013]"
          }
        }
      },
      "gt0011": {
        "id": "gt0011",
        "model_id": "openEHR-EHR-OBSERVATION.lab_test_psa.v1",
        "template_id": "openEHR-EHR-OBSERVATION.lab_test_psa.v1",
        "type": "INPUT",
        "elements": {
          "gt0012": {
            "id": "gt0012",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          }
        }
      },
      "gt0013": {
        "id": "gt0013",
        "model_id": "openEHR-EHR-OBSERVATION.gleason_score_for_prostate_cancer.v1",
        "template_id": "openEHR-EHR-OBSERVATION.gleason_score_for_prostate_cancer.v1",
        "type": "INPUT",
        "elements": {
          "gt0014": {
            "id": "gt0014",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]/items[at0007]"
          },
          "gt0015": {
            "id": "gt0015",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0005]/items[at0008]"
          }
        }
      },
      "gt0016": {
        "id": "gt0016",
        "model_id": "openEHR-EHR-OBSERVATION.prostate_cancer_tnm_staging.v1",
        "template_id": "openEHR-EHR-OBSERVATION.prostate_cancer_tnm_staging.v1",
        "type": "INPUT",
        "elements": {
          "gt0017": {
            "id": "gt0017",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          }
        }
      },
      "gt0021": {
        "id": "gt0021",
        "model_id": "openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk.v1",
        "template_id": "openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk.v1",
        "type": "INPUT",
        "elements": {
          "gt0022": {
            "id": "gt0022",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          }
        }
      },
      "gt0023": {
        "id": "gt0023",
        "model_id": "openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk.v1",
        "template_id": "openEHR-EHR-OBSERVATION.ucsf_capra_for_prostate_cancer_risk.v1",
        "type": "OUTPUT",
        "elements": {
          "gt0024": {
            "id": "gt0024",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          },
          "gt0025": {
            "id": "gt0025",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0010]"
          },
          "gt0026": {
            "id": "gt0026",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0011]"
          },
          "gt0027": {
            "id": "gt0027",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0012]"
          },
          "gt0028": {
            "id": "gt0028",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0013]"
          },
          "gt0029": {
            "id": "gt0029",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0008]"
          }
        }
      },
      "gt0052": {
        "id": "gt0052",
        "model_id": "openEHR-EHR-EVALUATION.ucsf_capra_for_prostate_cancer_assessment.v1",
        "template_id": "openEHR-EHR-EVALUATION.ucsf_capra_for_prostate_cancer_assessment.v1",
        "type": "OUTPUT",
        "elements": {
          "gt0053": {
            "id": "gt0053",
            "path": "/data[at0001]/items[at0002]"
          },
          "gt0054": {
            "id": "gt0054",
            "path": "/data[at0001]/items[at0020]"
          },
          "gt0055": {
            "id": "gt0055",
            "path": "/data[at0001]/items[at0028]"
          },
          "gt0056": {
            "id": "gt0056",
            "path": "/data[at0001]/items[at0033]"
          },
          "gt0057": {
            "id": "gt0057",
            "path": "/data[at0001]/items[at0024]"
          },
          "gt0058": {
            "id": "gt0058",
            "path": "/data[at0001]/items[at0032]"
          },
          "gt0059": {
            "id": "gt0059",
            "path": "/data[at0001]/items[at0034]"
          },
          "gt0060": {
            "id": "gt0060",
            "path": "/data[at0001]/items[at0004]"
          }
        }
      }
    },
    "rules": {
      "gt0018": {
        "id": "gt0018",
        "priority": 21,
        "when": [
          "$gt0008|Birthdate|!=null"
        ],
        "then": [
          "$gt0010|Age|.unit='a'",
          "$gt0010|Age|.magnitude=$currentDateTime.year-$gt0008.year"
        ]
      },
      "gt0030": {
        "id": "gt0030",
        "priority": 20,
        "when": [
          "$gt0010|Age|<50,a"
        ],
        "then": [
          "$gt0025|Age score|=0|local::at0014|< 50 years|"
        ]
      },
      "gt0031": {
        "id": "gt0031",
        "priority": 19,
        "when": [
          "$gt0010|Age|>=50,a"
        ],
        "then": [
          "$gt0025|Age score|=1|local::at0015|≥ 50 years|"
        ]
      },
      "gt0032": {
        "id": "gt0032",
        "priority": 18,
        "when": [
          "$gt0012|PSA value at diagnosis|<6,ng/mL"
        ],
        "then": [
          "$gt0026|PSA at diagnosis score|=0|local::at0016|< 6|"
        ]
      },
      "gt0033": {
        "id": "gt0033",
        "priority": 17,
        "when": [
          "$gt0012|PSA value at diagnosis|<10,ng/mL",
          "$gt0012|PSA value at diagnosis|>=6,ng/mL"
        ],
        "then": [
          "$gt0026|PSA at diagnosis score|=1|local::at0017|6  to 10|"
        ]
      },
      "gt0034": {
        "id": "gt0034",
        "priority": 16,
        "when": [
          "$gt0012|PSA value at diagnosis|<20,ng/mL",
          "$gt0012|PSA value at diagnosis|>=10,ng/mL"
        ],
        "then": [
          "$gt0026|PSA at diagnosis score|=2|local::at0018|10 to 20|"
        ]
      },
      "gt0035": {
        "id": "gt0035",
        "priority": 15,
        "when": [
          "$gt0012|PSA value at diagnosis|<=30,ng/mL",
          "$gt0012|PSA value at diagnosis|>=20,ng/mL"
        ],
        "then": [
          "$gt0026|PSA at diagnosis score|=3|local::at0019|20 to 30|"
        ]
      },
      "gt0036": {
        "id": "gt0036",
        "priority": 14,
        "when": [
          "$gt0012|PSA value at diagnosis|>30,ng/mL"
        ],
        "then": [
          "$gt0026|PSA at diagnosis score|=4|local::at0020|> 30|"
        ]
      },
      "gt0040": {
        "id": "gt0040",
        "priority": 13,
        "when": [
          "((($gt0017|T stage|==2|local::at0006|T2a|)||($gt0017|T stage|==3|local::at0007|T2b|))||($gt0017|T stage|==4|local::at0008|T2c|))||($gt0017|T stage|==1|local::at0005|T1c|)"
        ],
        "then": [
          "$gt0028|Prostate T staging score|=0|local::at0024|T1 or T2|"
        ]
      },
      "gt0041": {
        "id": "gt0041",
        "priority": 12,
        "when": [
          "$gt0017|T stage|==5|local::at0009|T3|"
        ],
        "then": [
          "$gt0028|Prostate T staging score|=1|local::at0025|T3a|"
        ]
      },
      "gt0042": {
        "id": "gt0042",
        "priority": 11,
        "when": [
          "$gt0022|Percent biopsy cores positive for cancer|!=null"
        ],
        "then": [
          "$gt0024|Percent biopsy cores positive for cancer|=$gt0022|Percent biopsy cores positive for cancer|"
        ]
      },
      "gt0039": {
        "id": "gt0039",
        "priority": 10,
        "when": [
          "($gt0014|Primary|==5|local::at0015|Few or no recognizable glands.|)||($gt0014|Primary|==4|local::at0014|Few recognizable glands.|)"
        ],
        "then": [
          "$gt0027|Gleason pattern score|=3|local::at0023|4 or 5 pattern in primary|"
        ]
      },
      "gt0038": {
        "id": "gt0038",
        "priority": 9,
        "when": [
          "!fired($gt0039)",
          "($gt0015|Secondary|==5|local::at0021|Few or no recognizable glands.|)||($gt0015|Secondary|==4|local::at0020|Few recognizable glands|)"
        ],
        "then": [
          "$gt0027|Gleason pattern score|=1|local::at0022|4 or 5 pattern in secondary|"
        ]
      },
      "gt0045": {
        "id": "gt0045",
        "priority": 8,
        "when": [
          "!fired($gt0038)",
          "!fired($gt0039)"
        ],
        "then": [
          "$gt0027|Gleason pattern score|=0|local::at0021|No 4 or 5 pattern present|"
        ]
      },
      "gt0044": {
        "id": "gt0044",
        "priority": 7,
        "then": [
          "$gt0029|Total score|.magnitude=$gt0024.value+$gt0025.value+$gt0026.value+$gt0027.value+$gt0028.value"
        ]
      },
      "gt0061": {
        "id": "gt0061",
        "priority": 6,
        "when": [
          "$gt0029|Total score|==0"
        ],
        "then": [
          "$gt0060|Managment|=0|local::at0011|Consider routine surveillance.|",
          "$gt0053|Risk level|=0|local::at0015|Very low risk|",
          "$gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood|=0|local::at0021|99.3%|",
          "$gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=0|local::at0029|99.7%|",
          "$gt0056|Score interpretation: 5 Year Overall survival % likelihood|=0|local::at0041|92.5%|",
          "$gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood|=0|local::at0025|97.5%|",
          "$gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=0|local::at0038|97.1%|",
          "$gt0059|Score interpretation: 10 Year Overall survival % likelihood|=0|local::at0035|71.4%|"
        ]
      },
      "gt0062": {
        "id": "gt0062",
        "priority": 5,
        "when": [
          "$gt0029|Total score|<=2",
          "$gt0029|Total score|>=1"
        ],
        "then": [
          "$gt0060|Managment|=1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|",
          "$gt0053|Risk level|=1|local::at0016|Low risk|",
          "$gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood|=0|local::at0021|99.3%|",
          "$gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=0|local::at0029|99.7%|",
          "$gt0056|Score interpretation: 5 Year Overall survival % likelihood|=0|local::at0041|92.5%|",
          "$gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood|=0|local::at0025|97.5%|",
          "$gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=0|local::at0038|97.1%|",
          "$gt0059|Score interpretation: 10 Year Overall survival % likelihood|=0|local::at0035|71.4%|"
        ]
      },
      "gt0063": {
        "id": "gt0063",
        "priority": 4,
        "when": [
          "$gt0029|Total score|==3"
        ],
        "then": [
          "$gt0060|Managment|=1|local::at0012|Consider localized treatment (surgery or radiation alone, brachytherapy with or without external-beam therapy)|",
          "$gt0053|Risk level|=2|local::at0017|Intermediate risk|",
          "$gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood|=1|local::at0022|96.9%|",
          "$gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=1|local::at0030|98.6%|",
          "$gt0056|Score interpretation: 5 Year Overall survival % likelihood|=1|local::at0042|90.2%|",
          "$gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood|=1|local::at0026|93.3%|",
          "$gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=1|local::at0039|91.6%|",
          "$gt0059|Score interpretation: 10 Year Overall survival % likelihood|=1|local::at0036|59.7%|"
        ]
      },
      "gt0064": {
        "id": "gt0064",
        "priority": 3,
        "when": [
          "$gt0029|Total score|<=5",
          "$gt0029|Total score|>=4"
        ],
        "then": [
          "$gt0060|Managment|=2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|",
          "$gt0053|Risk level|=2|local::at0017|Intermediate risk|",
          "$gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood|=1|local::at0022|96.9%|",
          "$gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=1|local::at0030|98.6%|",
          "$gt0056|Score interpretation: 5 Year Overall survival % likelihood|=1|local::at0042|90.2%|",
          "$gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood|=1|local::at0026|93.3%|",
          "$gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=1|local::at0039|91.6%|",
          "$gt0059|Score interpretation: 10 Year Overall survival % likelihood|=1|local::at0036|59.7%|"
        ]
      },
      "gt0065": {
        "id": "gt0065",
        "priority": 2,
        "when": [
          "$gt0029|Total score|==6"
        ],
        "then": [
          "$gt0060|Managment|=2|local::at0013|Consider multimodal therapy (surgery with radiation, or radiation therapy with hormonal therapy).|",
          "$gt0053|Risk level|=3|local::at0018|High risk|",
          "$gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood|=2|local::at0023|90.4%|",
          "$gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=2|local::at0031|93.4%|",
          "$gt0056|Score interpretation: 5 Year Overall survival % likelihood|=2|local::at0043|78.7%|",
          "$gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood|=2|local::at0027|83.4%|",
          "$gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=2|local::at0040|79.1%|",
          "$gt0059|Score interpretation: 10 Year Overall survival % likelihood|=2|local::at0037|42.0%|"
        ]
      },
      "gt0066": {
        "id": "gt0066",
        "priority": 1,
        "when": [
          "$gt0029|Total score|>6"
        ],
        "then": [
          "$gt0054|Score interpretation: 5 Year Metastasis-free interval % likelihood|=2|local::at0023|90.4%|",
          "$gt0055|Score interpretation: 5 Year Prostate cancer-specific survival % likelihood|=2|local::at0031|93.4%|",
          "$gt0056|Score interpretation: 5 Year Overall survival % likelihood|=2|local::at0043|78.7%|",
          "$gt0057|Score interpretation: 10 Year Metastasis-free interval % likelihood|=2|local::at0027|83.4%|",
          "$gt0058|Score interpretation: 10 Year Prostate cancer-specific survival % likelihood|=2|local::at0040|79.1%|",
          "$gt0059|Score interpretation: 10 Year Overall survival % likelihood|=2|local::at0037|42.0%|",
          "$gt0053|Risk level|=4|local::at0019|Very High risk|",
          "$gt0060|Managment|=3|local::at0044|Consider either multimodal therapy OR hormonal therapy|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "sv": {
        "id": "sv",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "USCF CAPRA för prostatacancer",
            "description": "USCF CAPRA är en metod för prognostisk värdering av utfall bland patienter som genomgått behandling för prostatacancer.\n"
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Andel biopsier med cancerceller",
            "description": ""
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Andel biopsier med cancerceller",
            "description": ""
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Poängsumma",
            "description": ""
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Födelsedatum",
            "description": ""
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Ålder",
            "description": ""
          },
          "gt0012": {
            "id": "gt0012",
            "text": "PSA vid diagnos",
            "description": ""
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Primär",
            "description": ""
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Sekundär",
            "description": ""
          },
          "gt0017": {
            "id": "gt0017",
            "text": "T-stadium",
            "description": ""
          },
          "gt0018": {
            "id": "gt0018",
            "text": "Beräkna ålder"
          },
          "gt0022": {
            "id": "gt0022",
            "text": "Andel biopsier med cancerceller",
            "description": ""
          },
          "gt0024": {
            "id": "gt0024",
            "text": "Andel biopsier med cancerceller",
            "description": ""
          },
          "gt0025": {
            "id": "gt0025",
            "text": "Ålder - poäng",
            "description": ""
          },
          "gt0026": {
            "id": "gt0026",
            "text": "PSA vid diagnos - poäng",
            "description": ""
          },
          "gt0027": {
            "id": "gt0027",
            "text": "Gradering enligt Gleason - poäng",
            "description": ""
          },
          "gt0028": {
            "id": "gt0028",
            "text": "PSA vid diagnos - poäng",
            "description": ""
          },
          "gt0029": {
            "id": "gt0029",
            "text": "Poängsumma",
            "description": ""
          },
          "gt0030": {
            "id": "gt0030",
            "text": "Ålder - poäng - < 50 yrs"
          },
          "gt0031": {
            "id": "gt0031",
            "text": "Ålder - poäng ≥ 50 years"
          },
          "gt0032": {
            "id": "gt0032",
            "text": "PSA score < 6"
          },
          "gt0033": {
            "id": "gt0033",
            "text": "PSA score 6 to 10"
          },
          "gt0034": {
            "id": "gt0034",
            "text": "PSA score 10 to 20"
          },
          "gt0035": {
            "id": "gt0035",
            "text": "PSA score 20 to 30"
          },
          "gt0036": {
            "id": "gt0036",
            "text": "PSA score > 30"
          },
          "gt0037": {
            "id": "gt0037",
            "text": "Gradering enligt Gleason - poäng - ej 4 eller 5"
          },
          "gt0038": {
            "id": "gt0038",
            "text": "Gradering enligt Gleason - poäng - 4/5 in secondary"
          },
          "gt0039": {
            "id": "gt0039",
            "text": "Gradering enligt Gleason - poäng - 4/5 in primary"
          },
          "gt0040": {
            "id": "gt0040",
            "text": "PSA vid diagnos - poäng (T1 eller T2)"
          },
          "gt0041": {
            "id": "gt0041",
            "text": "PSA vid diagnos - poäng (T3a)"
          },
          "gt0042": {
            "id": "gt0042",
            "text": "Andel biopsier med cancerceller"
          },
          "gt0043": {
            "id": "gt0043",
            "text": "Andel biopsier med cancerceller >= 34%"
          },
          "gt0044": {
            "id": "gt0044",
            "text": "Beräkna poängsumma"
          },
          "gt0045": {
            "id": "gt0045",
            "text": "Gradering enligt Gleason  - ej 4 eller 5"
          },
          "gt0051": {
            "id": "gt0051",
            "text": "Copy of Prostate T staging (T3a)",
            "description": ""
          },
          "gt0053": {
            "id": "gt0053",
            "text": "Risknivå",
            "description": "As the managment of prostate cancer patients is dependant on finer grained categories of risk levels, these have been assigned by splitting Very low risk and Low risk with scores of 0 and 1-2 respectively. For High and Very High risk, the scores are 6-8 and > 8 respectively."
          },
          "gt0054": {
            "id": "gt0054",
            "text": "Metastasfritt intervall - 5 år (%)",
            "description": "5 Year Metastasis-free interval % likelihood (95% CI)"
          },
          "gt0055": {
            "id": "gt0055",
            "text": "Överlevnad, prostatacancer - 5 år (%)",
            "description": "Prostate cancer–specific survival\r\n% likelihood (95% CI)"
          },
          "gt0056": {
            "id": "gt0056",
            "text": "Överlevnad, totalt - 5 år (%)",
            "description": "Overall survival % likelihood (95% CI)"
          },
          "gt0057": {
            "id": "gt0057",
            "text": "Metastasfritt intervall - 10 år (%)",
            "description": "10 Year Metastasis-free interval % likelihood (95% CI)"
          },
          "gt0058": {
            "id": "gt0058",
            "text": "Överlevnad, prostatacancer - 10 år (%)",
            "description": "Prostate cancer–specific survival\r\n% likelihood (95% CI)"
          },
          "gt0059": {
            "id": "gt0059",
            "text": "Överlevnad, totalt - 10 år (%)",
            "description": "Overall survival % likelihood (95% CI)"
          },
          "gt0060": {
            "id": "gt0060",
            "text": "Rekommendation",
            "description": "As the managment of prostate cancer patients is dependant on finer grained categories of risk levels, these have been assigned by splitting Very low risk and Low risk with scores of 0 and 1-2 respectively. For High and Very High risk, the scores are 6-8 and > 8 respectively."
          },
          "gt0061": {
            "id": "gt0061",
            "text": "CDS mycket låg risk",
            "description": ""
          },
          "gt0062": {
            "id": "gt0062",
            "text": "CDS låg risk",
            "description": ""
          },
          "gt0063": {
            "id": "gt0063",
            "text": "CDS mellanrisk score 3",
            "description": ""
          },
          "gt0064": {
            "id": "gt0064",
            "text": "CDS mellanrisk score 4-5",
            "description": ""
          },
          "gt0065": {
            "id": "gt0065",
            "text": "CDS hög risk score 6",
            "description": ""
          },
          "gt0066": {
            "id": "gt0066",
            "text": "CDS mycket hög risk score > 6",
            "description": ""
          }
        }
      },
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "UCSF CAPRA for prostate cancer risk",
            "description": "The UCSF CAPRA score for prostate cancer risk provides an outcome prediction for patients with prostate cancer, post treatment"
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Percent biopsy cores positive for cancer",
            "description": "Percent biopsy cores positive for cancer"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Percent biopsy cores positive for cancer",
            "description": "Percent biopsy cores positive for cancer"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Total score",
            "description": "Sum of the individual scores. The score range is 0 to 10"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Birthdate",
            "description": "The patient's date of birth."
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Age",
            "description": "Age in years, and for babies: months, weeks or days"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "PSA value at diagnosis",
            "description": "Lab test result of prostate-specific antigen (PSA)"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Primary",
            "description": "*"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "Secondary",
            "description": "*"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "T stage",
            "description": "Staging the size of the primary tumor"
          },
          "gt0018": {
            "id": "gt0018",
            "text": "Calculate Age"
          },
          "gt0022": {
            "id": "gt0022",
            "text": "Percent biopsy cores positive for cancer",
            "description": "Percent biopsy cores positive for cancer"
          },
          "gt0024": {
            "id": "gt0024",
            "text": "Percent biopsy cores positive for cancer",
            "description": "Percent biopsy cores positive for cancer"
          },
          "gt0025": {
            "id": "gt0025",
            "text": "Age score",
            "description": "Age score"
          },
          "gt0026": {
            "id": "gt0026",
            "text": "PSA at diagnosis score",
            "description": "PSA at diagnosis (ng/mL)"
          },
          "gt0027": {
            "id": "gt0027",
            "text": "Gleason pattern score",
            "description": "Gleason Score pattern (primary or secondary)"
          },
          "gt0028": {
            "id": "gt0028",
            "text": "Prostate T staging score",
            "description": "T1 staging in prostate cancer"
          },
          "gt0029": {
            "id": "gt0029",
            "text": "Total score",
            "description": "Sum of the individual scores. The score range is 0 to 10"
          },
          "gt0030": {
            "id": "gt0030",
            "text": "Age score - < 50 yrs"
          },
          "gt0031": {
            "id": "gt0031",
            "text": "Age score ≥ 50 years"
          },
          "gt0032": {
            "id": "gt0032",
            "text": "PSA score < 6"
          },
          "gt0033": {
            "id": "gt0033",
            "text": "PSA score 6 to 10"
          },
          "gt0034": {
            "id": "gt0034",
            "text": "PSA score 10 to 20"
          },
          "gt0035": {
            "id": "gt0035",
            "text": "PSA score 20 to 30"
          },
          "gt0036": {
            "id": "gt0036",
            "text": "PSA score > 30"
          },
          "gt0037": {
            "id": "gt0037",
            "text": "Gleason pattern - no 4 or 5"
          },
          "gt0038": {
            "id": "gt0038",
            "text": "Gleason pattern - 4/5 in secondary"
          },
          "gt0039": {
            "id": "gt0039",
            "text": "Gleason pattern - 4/5 in primary"
          },
          "gt0040": {
            "id": "gt0040",
            "text": "Prostate T staging (T1 or T2)"
          },
          "gt0041": {
            "id": "gt0041",
            "text": "Prostate T staging (T3a)"
          },
          "gt0042": {
            "id": "gt0042",
            "text": "Percent bopsy cores positive"
          },
          "gt0043": {
            "id": "gt0043",
            "text": "Percent bopsy cores positive >= 34%"
          },
          "gt0044": {
            "id": "gt0044",
            "text": "Calculate Total Score"
          },
          "gt0045": {
            "id": "gt0045",
            "text": "Gleason pattern - no 4 or 5"
          },
          "gt0051": {
            "id": "gt0051",
            "text": "Prostate T staging (T4)"
          },
          "gt0053": {
            "id": "gt0053",
            "text": "Risk level",
            "description": "As the managment of prostate cancer patients is dependant on finer grained categories of risk levels, these have been assigned by splitting Very low risk and Low risk with scores of 0 and 1-2 respectively. For High and Very High risk, the scores are 6-8 and > 8 respectively."
          },
          "gt0054": {
            "id": "gt0054",
            "text": "Score interpretation: 5 Year Metastasis-free interval % likelihood",
            "description": "5 Year Metastasis-free interval % likelihood (95% CI)"
          },
          "gt0055": {
            "id": "gt0055",
            "text": "Score interpretation: 5 Year Prostate cancer-specific survival % likelihood",
            "description": "Prostate cancer–specific survival\r\n% likelihood (95% CI)"
          },
          "gt0056": {
            "id": "gt0056",
            "text": "Score interpretation: 5 Year Overall survival % likelihood",
            "description": "Overall survival % likelihood (95% CI)"
          },
          "gt0057": {
            "id": "gt0057",
            "text": "Score interpretation: 10 Year Metastasis-free interval % likelihood",
            "description": "10 Year Metastasis-free interval % likelihood (95% CI)"
          },
          "gt0058": {
            "id": "gt0058",
            "text": "Score interpretation: 10 Year Prostate cancer-specific survival % likelihood",
            "description": "Prostate cancer–specific survival\r\n% likelihood (95% CI)"
          },
          "gt0059": {
            "id": "gt0059",
            "text": "Score interpretation: 10 Year Overall survival % likelihood",
            "description": "Overall survival % likelihood (95% CI)"
          },
          "gt0060": {
            "id": "gt0060",
            "text": "Managment",
            "description": "As the managment of prostate cancer patients is dependant on finer grained categories of risk levels, these have been assigned by splitting Very low risk and Low risk with scores of 0 and 1-2 respectively. For High and Very High risk, the scores are 6-8 and > 8 respectively."
          },
          "gt0061": {
            "id": "gt0061",
            "text": "Set Very low risk"
          },
          "gt0062": {
            "id": "gt0062",
            "text": "Set Low risk"
          },
          "gt0063": {
            "id": "gt0063",
            "text": "Set Intermediate risk score 3"
          },
          "gt0064": {
            "id": "gt0064",
            "text": "Set Intermediate risk score 4-5"
          },
          "gt0065": {
            "id": "gt0065",
            "text": "Set High risk score 6"
          },
          "gt0066": {
            "id": "gt0066",
            "text": "Set Very high risk score > 6"
          }
        }
      }
    }
  }
}
